Axsome Therapeutics, Inc.
AXSM
Pozycja w akcjach
#2363
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Cena akcji
$159.65
Kapitalizacja rynkowa
$8.36B
Zmiana (1 dzień)
2.46%
Zmiana (1 rok)
21.31%
Kraj
US
Handel Axsome Therapeutics, Inc. (AXSM)
Kategoria
Healthcare
Zyski dla Axsome Therapeutics, Inc. (AXSM)
Zyski w Jun 2026 TTM: $-191.09M
Według najnowszych raportów finansowych Axsome Therapeutics, Inc., obecny zysk firmy wynosi $-191.09M. W roku 2023 firma osiągnęła zysk w wysokości $-238.28M, spadek w porównaniu do zysku z roku 2022, który wynosił $-187.13M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Axsome Therapeutics, Inc. od 2013 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-191.09M | -33.45% |
| 2024 | $-287.13M | 20.50% |
| 2023 | $-238.28M | 27.33% |
| 2022 | $-187.13M | 43.50% |
| 2021 | $-130.40M | 26.73% |
| 2020 | $-102.90M | 50.56% |
| 2019 | $-68.35M | 120.71% |
| 2018 | $-30.97M | 6.99% |
| 2017 | $-28.94M | 6.40% |
| 2016 | $-27.20M | 157.60% |
| 2015 | $-10.56M | 75.98% |
| 2014 | $-6.00M | 176.95% |
| 2013 | $-2.17M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -2,860.48% |
US
|
|
| $-3.09B | 1,515.50% |
US
|
|
| $-4.02B | 2,001.77% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,120.82% |
NL
|
